Hälsa i EUs ramprogramHälsa i EUs ramprogram FP7

En värld en hälsaGunnar Sandbergg

Gunnar Sandberg Dr Programme Manager

Health DivisionVINNOVAVINNOVA

Gunnar.Sandberg@VINNOVA.sewww.VINNOVA.se

2011-04-07Bild 1

VINNOVA är Sveriges inno ationsm ndighetinnovationsmyndighet

2011-04-07Bild 2

VINNOVA klVINNOVA utvecklar Sveriges innovations-gkraft för hållbar tillväxt

2011-04-07Bild 3

Investering i FoI Innovations-kapacitet

Verifiering

FoI projekt Test- och

Coaching

FoI-projekt för ökad tillväxt

kapaciteti SMF

Nyttiggörande

FoI-projekt demositerökad tillväxt

Deltagande i internationella

samarbeten

Starka FoI-miljöer

InnovationsInnovations--kraftkraft

InnovationsInnovations--kraftkraft

Högskolor och universitet Bilaterala FoI-kraftkraftkraftkraft

Effektiv

Statliga aktörer

NäringslivForsknings- Global

Bilaterala FoIsamarbeten

Svenskt deltagande iEffektiv

samverkanForsknings

institut

IntermediärerOmvärldsanalys

Katalyserande mötesplatser

Global uppkoppling

deltagande i EU:s FoU-program

mötesplatserStrategi-

processer

2011-04-07Bild 4

Policyutveckling

FÖRDELNINGFÖRDELNING

500-250-500200-250150-200125-150

PER LÄNPER LÄN

miljoner kronor investerade

100-12575-10050-7520-500-20(mkr)

VINNOVA i svensk FoI 2009FÖRDELNINGFÖRDELNINGPER SEKTORPER SEKTOR

892

802800

900

1 000

Utb t l t b l ( k )

PER SEKTORPER SEKTOR

587

252

634

300

400

500

600

700 Utbetalat belopp (mkr)

Antal utbetalade projekt

252

125

216176

49

146

0

100

200

300

Högskolor och i it t

Privata företag Forskningsinstitut Offentlig förvaltning Övriga

2011-04-07Bild 5

universitet

Målet är ökad k k k f hkonkurrenskraft hos forskare och företag i gSverige

2011-04-07Bild 6

FP7 budget - 54,582 (incl. Euroatom)Euratom

4 061

g ( )(EUR billion, 2004 constant prices)

JRC1,751

4,061

C iCapacities

4,217

Cooperation32,365

People

Ideas7 46

People4,728

7,46

FP7 2007 2013FP7 2007-2013‘Cooperation’ budgetCooperation budget

I Cooperation

Budget (€ million, 2004

t t i )I. Cooperation constant prices)

1. Health 60502. KBBE Food, and agriculture and Biotechnology 19353. Information and Communication Technologies 91104. Nanotechnologies, materials and production 35005. Energy 23006. Environment 19007. Transport 41808. Socio-economic and Humanities 6109. Security & Space 2780

Total 32365** Not including non-nuclear activities of the Joint Research Centre: €1 751 million

H lthHealthCollaborative research in the Health theme

Main policy drivers:• Improving health of European citizens• Improving health of European citizens• Increasing competitiveness of European health-related industries

and businesses• Addressing global health issues, including emerging epidemics

Budget:• €6.1 billion over 7 years (2007-2013)

The Health Theme ‐ Three main activities (“pillars”)

Activity 1: Activity 2: Activity 3:y

Biotechnology, generic tools

& technologies

y

Translating research for

human health

y

Optimising the delivery

of health care

The Innovative Medicines & technologies

for health human health of health care ed c es

Initiative

cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issues

Activity 4: Support actions & response to policy needs

Pandemic in FP7FLUDRUGSTRATEGY- Combating influenza using a novel drug strategy Duration: 48 months

Expected EU contribution: €6 millionCoordinator: Heather Marshall-Heyman VIRONOVA AB (Sweden) heather marshall-Coordinator: Heather Marshall-Heyman, VIRONOVA AB (Sweden), heather.marshall-heyman@vironova.com9 Partners from 7 European countries: Sweden, Switzerland, Bulgaria, The Netherlands, Lithuania, Germany, Italy

www. fludrugstrategy.com

The objective of the project is to develop antiviral compounds that inhibit the influenza A virus using a j p j p p gnovel drug development strategy.

The project will bring together 1 experts from highly diverse fields in order to create a logical flow of work from the identification of1. experts from highly diverse fields in order to create a logical flow of work from the identification of

small organic compounds that inhibit the maturation process2. design and synthesis of these compounds and derivatives thereof3. observation and analysis of the effects of these compounds on particle formation; 4. testing of their efficacy in combating the influenza virus, employing unique patented technology;

and, finally, to the production of novel antiviral drugs.

07/04/2011

Swedish Project s in FP 7 covering area pandemic influenza

1 FAST-XDR-DETECT Title: Development of a two-approach plate system for the fast and 1. FAST XDR DETECT Title: Development of a two approach plate system for the fast and simultaneous detection of MDR and XDR M. tuberculosis Research area: HEALTH-2007-2.3.2-3 Development of fast tests for the diagnosis of Multi-Drug-Resistant strains of HIV, malaria and tuberculosis and of latent tuberculosis infection (LTBI) Project start date: [2008-02-01] Swe. SMI

2 FERFLU EXPRESS Title: Investigation of influenza immune responses and vaccine efficacy 2. FERFLU EXPRESS Title: Investigation of influenza immune responses and vaccine efficacy correlates by global expression profiling and immunological analyses in the ferret model of influenza Research area: FP7-PEOPLE-2009-IIF Marie Curie Action: "International Incoming Fellowships" Project start date: [2010-09-01] SWE KI

3 VIRUS ENTRY Titl M l l h i f ll t f l d i R h 3. VIRUS ENTRY Title: Molecular mechanisms of cell entry of enveloped viruses Research area:FP7-PEOPLE-ITN-2008 Marie Curie Action: "Networks for Initial Training" Project start date: [2009-10-01] SWE KI

4. FLUDRUGSTRATEGY Title: Combating influenza using a novel drug strategy Research area:HEALTH-2007-2.3.3-1 Development of broadly protective influenza vaccine candidates,HEALTH-2007-2.3.3-7 Supporting highly innovative inter-disciplinary research on influenza Project start date:[2008-03-01] SWE Vironova, Beactica

07/04/2011

Antibiotic resistance in FP733 projectsPAR Predicting antibiotic resistance

EC contribution : € 6 000 000 Duration : 36 monthsEC contribution : € 6,000,000 Duration : 36 months Coordinator Uppsala University, Sweden Dan Andersson, Diarmaid Hughes

Starting date : January 2010 Funding scheme : Large-scale integrating project (IP) Keywords : infectious disease, bacteria, antibioticKeywords : infectious disease, bacteria, antibioticresistance, virulence, fitness, transmission, mathematical modelling, mutation, plasmid Project web-site : http://www.imbim.uu.se/PAR/index.html

The expected achievements are to: Generate parameter values for most of the bacterial factors we expect to be important

for resistance development. Generate new understanding of how different levels in the pathways leading from drug

sensitivity to drug resistance and high fitness are integrated. Provide the experimental knowledge required to model and perform risk assessments

for the development and spread of antibiotic resistance. P id th k l d b i d t d l l di ti t t t f Provide the knowledge base required to develop novel diagnostic test systems for

bacteria and compounds with a high risk of resistance development. Develop and implement the use of different approaches to measure bacterial

transmission between hoststransmission between hosts.

07/04/2011

S d P jA tibi ti i t (1)Swed. ProjAntibiotic resistance (1) 1. ANTIRESDEV Titl Th ff t f tibi ti d i i t ti th d i t f tibi ti i t t b t i i h d Title: The effects of antibiotic administration on the emergence and persistence of antibiotic-resistant bacteria in humans and

on the composition of the indigenous microbiotas at various body sites Research area: HEALTH-2009-2.3.1-2 Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the

human host SWE: KI Project start date: [2009-11-01] Project start date: [2009 11 01] 2. PNEUMOPATH Title:A comprehensive dissection of pneumococcal-host interactions Research area: HEALTH-2007-2.3.1-2 Host-pathogen interactions in infections by Streptococcus pneumoniae Project start date: [2009 03 01] SWE SMI Project start date: [2009-03-01] SWE SMI 3. PAR Title: Predicting antibiotic resistance Research area: HEALTH-2009-2.3.1-2 Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the

human hosthuman host Project start date: [2010-04-01] SWE UPPU 4. ACUSEP Title: Integrated whole blood acoustophoresis and homogeneous nucleic acid detection cartridge for rapid sepsis diagnostics Research area: HEALTH 2010 1 2 1 Tools for the identification and the detection of biomarkers in clinical samples and patients Research area: HEALTH.2010.1.2-1 Tools for the identification and the detection of biomarkers in clinical samples and patients.

FP7-HEALTH-2010-two-stage Project start date: [2010-12-01] SWE LUND

07/04/2011

S d P jA tibi ti i t A tibi ti i t (2)Swed. ProjAntibiotic resistanceAntibiotic resistance (2) 5. MARIBACT Title: Occurrence, distribution and cost of antibiotic resistance in marine sediment bacteria Research area: FP7-PEOPLE-2009-RG Marie CurieAction: "Reintegration Grants" Research area: FP7 PEOPLE 2009 RG Marie Curie Action: Reintegration Grants Project start date: [2010-04-01] SWE GU 6. DEBUGIT Title: Detecting and eliminating bacteria using information technologies Research area: ICT-2007 5 2Advanced ICT for risk assessment and patient safety Research area: ICT-2007.5.2 Advanced ICT for risk assessment and patient safety Project start date: [2008-01-01] SWE LINU 7. THERAEDGE Title:An integrated platform enabling Theranostic applications at the point of primary care Research area: ICT 2007 5 1 Personal health systems for monitoring and point of care diagnostics Research area: ICT-2007.5.1 Personal health systems for monitoring and point-of-care diagnostics Project start date: [2008-03-01] SWE LINU 8. INTOPSENS Title:A highly integrated optical sensor for point of care label free identification of pathogenic bacteria strains and their antibiotic

resistanceresistance Research area: ICT-2007.3.5 Photonic components and subsystems Project start date: [2008-09-01] SWE KTH 9. NABATIVI Title: Novel approaches to bacterial target identification validation and inhibition Title: Novel approaches to bacterial target identification, validation and inhibition Research area: HEALTH-2007-2.1.2-5 Multidisciplinary fundamental genomics and molecular biology approaches to study basic

biological processes relevant to health and diseases,HEALTH-2007-2.3.1-1 Novel targets for drugs against Gram negative bacteria

Project start date: [2009-02-01] SWE ACTARAB Project start date: [2009 02 01] SWE ACTAR AB

07/04/2011

HealthWorkprogramme 2012HealthWorkprogramme 2012. Pillar 1 Personalised medicines, solid organ transplantation, bioartifical, g p ,

organ, stem cell based therapies in regenerative medicine, nucleic aciddelivery as innovative approach

Pillar 2 Rare diseases, biomarkers for diseases affectingelderly, systems biology, systems medicine, systems biology and comparitive genomics studying ageing, multiple diseases amongcomparitive genomics studying ageing, multiple diseases amongelderly, diagnostic for infectious diseases, ERA net on infectiousdiseases, Coinfection of HIV/AIDS, malaria, tuberculosis and /or hepatitis, Comorbidity between infectious and non communicablep , ydiseases, prevention and treatment for HIV/AIDS, diabetes, development of orphan drugs, other chronic diseases

European and Developing Countries Trial Partnership (EDCTP2) European and Developing Countries Trial Partnership (EDCTP2) Budget.600 millions Euro

07/04/2011

Joint Programming (JP)Joint Programming (JP)

N tt i t t fö t ti llt b t i E Nytt instrument för transnationellt samarbete i Europa. EU förfogar över för forskning bara utgör 5-6% av alla tillgängliga

medel. Resten –hela 94-95% kontrolleras av medlemsstaterna. 2 viktiga Joint Programming-initiativ, inom Health JP

N d ti Di (JPND) h JP A ti i bi lNeurodegenerative Diseases (JPND) och JP AntimicrobialResistance. (JPAMR)För JPAMR, är Sverige (VR) initiativtagare och den drivande kraften. , g ( ) gUtlysning 2012??

JPND, planeras en utlysning före sommaren.

2011-04-07Bild 17

IMI 20121 Pharmacogenetics and Taxonomy of Human Diseases1. Pharmacogenetics and Taxonomy of Human Diseases2. Rare Diseases and Stratified Therapies3 S t A h i D R h3. Systems Approaches in Drug Research4. “Beyond High Throughput Screening”-

Pharmacological Interactions at the Molecular LevelPharmacological Interactions at the Molecular Level5. API Technology (Drug Compound Development)6 Advanced Formulations6. Advanced Formulations7. Stem Cells for Drug Development and Toxicity

ScreeningScreening8. Integration of Imaging Techniques into Drug Research

2011-04-07Bild 18

More informationMore informationwww.vinnova.sewww.vinnova.se

www cordis europa euwww.cordis.europa.eu

2011-04-07Bild 19

Pilot Joint Programming

Joint Programming Initiative on “Neurodegenerativeg g gDiseases, in particular Alzheimer” (JPND)

• Launched in July 2008

• Council Conclusions of 3 December 2009: adopted the JPND• Council Conclusions of 3 December 2009: adopted the JPND

JPND current activities

• Mapping exercise has started (contribution of all member countries requested)

• 3 workshops planned (March 2011): basic, clinical and healthcare

• Basis for the Strategic Research Agenda to be completed and approved in 2011

JPND pilot call

• Discussion on the first pilot call to be launched by the JPND (outside th St t i R h A d )the Strategic Research Agenda)

• Focus on standardization of biomarkers in neurodegenerativeFocus on standardization of biomarkers in neurodegenerative diseases (indicative)

• Potential participation: at least 10 countries, € 6-8 million (indicative)

JPND indicative timelines

• 2011 L h f Pil t C ll– Launch of Pilot Call

– Strategic Research Agenda completed

• 2012– Pilot project started

Calls from Strategic Research Agenda– Calls from Strategic Research Agenda

• 2013– New projects started

State-of-play of the JPND

• Led by France (INSERM): Prof Philippe AMOUYEL is the Chair of theLed by France (INSERM): Prof. Philippe AMOUYEL is the Chair of the Management Board

• Addresses basic science, clinical research and healthcare research• 23 participating countries (all represented at the Management Board)• Work with an Executive Board and a Scientific Advisory Board (15

experts)experts)

www.neurodegenerationresearch.eu

Joint Programmingl t d i 2009

3 other JPIs selected in 2009 and launched in 2010

selected in 2009

• “Healthy diet for a healthy life”

• “Agriculture, Food Security and Climate Change”

• “Cultural Heritage and global change: a new challenge for Europe”

Joint Programmingselected in 2010

6 additional JPIs selected in 2010 (Council of 26 May)• “Anti-Microbial drug Resistance” (JPAMR)• “Healthy Ageing – More Years, Better Lives” (Demographic Change)• “Urban Europe”

“Connecting Climate Kno ledge for E rope” (Clik'EU)• “Connecting Climate Knowledge for Europe” (Clik'EU)• “Water Challenges for a Changing World”• “Healthy and Productive Seas and Oceans”Healthy and Productive Seas and Oceans

State-of-play of the JPAMR

• Led by Sweden: Prof. Mats ULFENDAHL is the Chair of the interim M t B dManagement Board

• Main focus on bacterial antibiotic resistance and human medicineMain focus on bacterial antibiotic resistance and human medicine (both basic and applied research)

• 15 participating countries

• An interim Management Board and an Executive Board have been set• An interim Management Board and an Executive Board have been set up

• Terms of Reference agreed on

Next activities of the JPAMR

• Draft Vision Document under discussion for spring 2011

• Scientific Advisory Board to be set up in 2011 (National Expert Panels will appoint scientists from both EU and non-EU)

• Stakeholder Advisory Board to be set up later

• Mapping exercise is starting and will conclude in 2011• Mapping exercise is starting and will conclude in 2011

• Scientific Workshop in May 2011 (Brussels)p y ( )• Public consultation on priorities to be launched 2011• Draft Strategic Research Agenda before end of 2011

Other JPIs relevant for Health

“Healthy diet for a healthy life”Healthy diet for a healthy life• Led by Germany & The Netherlands – 20 countries

participatingp p g• Management Board established• Pilot Call foreseen for 2011• DG RTD, Directorate E “Biotechnologies, Agriculture,

Food” is chef de file

“Healthy Ageing – More Years, Better Lives”y g g ,• Led by Germany – 15 countries participating• DG INFSO is chef de file